cardiovascularКардиоваскулярная терапия и профилактикаCardiovascular Therapy and Prevention1728-88002619-0125«SILICEA-POLIGRAF» LLCcardiovascular-1093Research ArticleМНЕНИЕ ПО ПРОБЛЕМЕOPINION ON A PROBLEMВыбор статина для гиполипидемической терапии с позиций клинической фармакологии и доказательной медициныStatin choice for lipid6lowering therapy: clinical pharmacology and evidence-based medicine positionНедогодаС. В.NedogodaS. V.nedogodasv@rambler.ruВолгоградский государственный медицинский университетVolgograd State Medical University20082002200871112115Copyright © Недогода С.В., 20082008Недогода С.В.Nedogoda S.V.Данная работа распространяется под лицензией Creative Commons Attribution 4.0.This work is licensed under a Creative Commons Attribution 4.0 License.https://cardiovascular.elpub.ru/jour/article/view/1093

Проанализированы особенности применения различных статинов с учетом их клинико6фармакологических характеристик. Особое внимание уделяется имеющейся доказательной базе применения аторвастатина и розувастатина. Отдельно предпринята попытка сравнить способность различных статинов уменьшать размеры атеросклеротической бляшки по данным внутрисосудистого ультразвукового исследования. Сделан вывод о существенных преимуществах гиполипидемической монотерапии с использованием «новых» статинов перед «старыми».

The features of various statins’ use are analysed taking into consideration their clinical and pharmacological parameters. The present evidence base on atorvastatin and rosuvastatin is emphasised. The author compares various statins in regard to their potential in atherosclerotic plaque reduction, according to intravascular ultrasound data. Substantial benefits of lipid-lowering monotherapy by “new” vs “old” statins are demonstrated.

статиныаторвастатинрозувастатинснижение риска осложненийвнутрисосудистое ультразвуковое исследованиеstatinsatorvastatinrosuvastatincomplication risk reductionintravascular ultrasound examinationReferencesJones P, Kafonek S, Laurora I, et al. Comparative dose efficacy study of atorvastatin versus simvastatin, pravastatin, lovastatin and fluvastatin in patients with hypercholesterolemia (The Curves study). Am J Cardiol 1998; 81: 582–7.Jones P, Kafonek S, Laurora I, et al. Comparative dose efficacy study of atorvastatin versus simvastatin, pravastatin, lovastatin and fluvastatin in patients with hypercholesterolemia (The Curves study). Am J Cardiol 1998; 81: 582–7.Nawrocki JW, Weiss SR, Davidson MH, et al. Reduction of LDL cholesterol by 25 % to 60 % in patients with primary hypercholesterolemia by atorvastatin a new HMS-CoA reductase inhibitor. Arterioscler Thromb Vasc Biol 1995; 15: 678–82.Nawrocki JW, Weiss SR, Davidson MH, et al. Reduction of LDL cholesterol by 25 % to 60 % in patients with primary hypercholesterolemia by atorvastatin a new HMS-CoA reductase inhibitor. Arterioscler Thromb Vasc Biol 1995; 15: 678–82.Smith DG, Leslie SJ, Szucs TD, et al. Cost of treating to a modified European Atherosclerosis Society LDL6C target. Comparison of atorvastatin with fluvastatin, pravastatin and simvastatin. (Treatto-Target Study). Clin Drug Invest 1999; 17: 185–93.Smith DG, Leslie SJ, Szucs TD, et al. Cost of treating to a modified European Atherosclerosis Society LDL6C target. Comparison of atorvastatin with fluvastatin, pravastatin and simvastatin. (Treatto-Target Study). Clin Drug Invest 1999; 17: 185–93.Athyros VG, Papageorgiou AA, Mercouris BR, et al. Treatment with atorvastatin to the National cholesterol educational program goal versus “usual” care in secondary coronary heart disease prevention: The GREek Atorvastatin and Coronary-heartdisease Evaluation Study (GREACE). Cur Med Res Opin 2002; 18: 220–8.Athyros VG, Papageorgiou AA, Mercouris BR, et al. Treatment with atorvastatin to the National cholesterol educational program goal versus “usual” care in secondary coronary heart disease prevention: The GREek Atorvastatin and Coronary-heartdisease Evaluation Study (GREACE). Cur Med Res Opin 2002; 18: 220–8.Nissen S, Tuzcu M, Schoenhagen P. Effect of Intensive Compared With Moderate Lipid6Lowering Therapy on Progression of Coronary Atherosclerosis. JAMA 2004; 291: 1071–80.Nissen S, Tuzcu M, Schoenhagen P. Effect of Intensive Compared With Moderate Lipid6Lowering Therapy on Progression of Coronary Atherosclerosis. JAMA 2004; 291: 1071–80.Okazaki S, Yokoyama T, Miyauchi K Early Statin Treatment in Patients With Acute Coronary Syndrome. Demonstration of the Beneficial Effect on Atherosclerotic Lesions by Serial Volumetric Intravascular Ultrasound Analysis During Half a Year After Coronary Event: The ESTABLISH Study. Circulation 2004; 110: 1061–8.Okazaki S, Yokoyama T, Miyauchi K Early Statin Treatment in Patients With Acute Coronary Syndrome. Demonstration of the Beneficial Effect on Atherosclerotic Lesions by Serial Volumetric Intravascular Ultrasound Analysis During Half a Year After Coronary Event: The ESTABLISH Study. Circulation 2004; 110: 1061–8.Nissen S, Nicholls S, Sipahi I. Effect of very high-intensity statin therapy on regression of coronary atherosclerosis. The ASTERIOD trial. JAMA 2006; 295: 1556–65.Nissen S, Nicholls S, Sipahi I. Effect of very high-intensity statin therapy on regression of coronary atherosclerosis. The ASTERIOD trial. JAMA 2006; 295: 1556–65.Newman BC, Palmary G, Sielbershats H, Szarek M. Safety of atorvastatin derived from analysis of 44 completed trail in 9,416 patients. Am J Cardiol 2003; 92: 670–6.Newman BC, Palmary G, Sielbershats H, Szarek M. Safety of atorvastatin derived from analysis of 44 completed trail in 9,416 patients. Am J Cardiol 2003; 92: 670–6.

The authors declare that there are no conflicts of interest present.